BioStock: Cantargia's 2025 was marked by Otsuka agreement and new leadership
After several years of focused development, 2025 became a pivotal year for Cantargia. At the centre were the divestment of the CAN10 programme to Japan’s Otsuka Pharmaceutical and the appointment of Dr Hilde Steineger as the company’s new CEO. We spoke with her to gain her perspective on the year that has passed.
Read the article at biostock.se:
https://biostock.se/en/2026/01/cantargias-2025-praglades-av-otsuka-avtal-och-nytt-ledarskap/
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/